For millions of patients, the "combined endoscopy" is a masterclass in medical efficiency. It is the consolidation of an esophagogastroduodenoscopy (EGD)—an examination of the upper gastrointestinal tract—and a colonoscopy—an examination of the lower GI tract—into a single session. From the patient’s perspective, the benefits are undeniable: one preparation, one sedation event, and a single day lost to recovery rather than two.
As health systems grapple with a looming specialist shortage—projected to leave a gap of nearly 1,400 gastroenterologists by 2037—this consolidation is rapidly evolving from a patient-centered convenience to a strategic operational necessity. However, beneath the surface of this logistical efficiency lies a troubling clinical reality: the upper GI exam is frequently treated as a secondary appendage to the colonoscopy, a "quick add-on" that lacks the rigorous quality infrastructure, standardized benchmarks, and technological scrutiny that have become the hallmark of lower GI care.
To ensure the future of gastroenterology remains patient-safe and clinically robust, the industry must pivot toward a new framework that treats the upper GI tract with the same precision, attention, and technological support currently reserved for the colon.
The Disparity in Clinical Infrastructure
In the world of gastroenterology, the colonoscopy has reigned supreme for decades. It is the gold standard for colorectal cancer screening, supported by a highly developed infrastructure of quality metrics. Clinicians measure their success through the Adenoma Detection Rate (ADR), cecal intubation rates, and standardized withdrawal times. These metrics are not merely suggestions; they are the bedrock of practice, enforced by professional societies and integrated into reimbursement models.
Conversely, the upper GI tract has historically been viewed through a different, less rigorous lens. In a combined procedure, the colonoscopy is almost always the "primary" event. The patient is there for cancer screening; the EGD is often appended as an afterthought. This hierarchy of importance has created a dangerous "shadow effect."
When a procedure is treated as a secondary task, clinical diligence can waver. Research into bidirectional endoscopy sequencing confirms this, indicating that procedural fatigue and endoscopist preference significantly impact upper GI outcomes in combined sessions. If an endoscopist is focused on the high-stakes, time-sensitive nature of a colonoscopy, the EGD may be performed with haste, sacrificing the thoroughness required to identify subtle lesions.
The Anatomical Challenge: Why the Stomach is Not the Colon
To understand why upper GI quality lags, one must first recognize the fundamental difference in the clinical tasks at hand.
In a colonoscopy, the practitioner is essentially "target hunting." The colon is a relatively uniform, tubular structure; the goal is to identify polyps on a predictable surface. Because the target is clear, the metrics for success are easily defined.
The upper GI tract, however, presents a far more complex landscape. The stomach and esophagus are characterized by folds, recesses, and intricate anatomical landmarks. The clinical task is not simply to "find" an abnormality, but to ensure 100% mucosal coverage of a highly variable environment.
The consequences of this gap in scrutiny are profound. Studies have shown that in nearly 69% of missed upper GI cancer cases, the endoscopist had actually recorded an image of the area where the cancer was later diagnosed. The malignancy was not invisible; it was simply not examined with the requisite focus. Consequently, upper GI cancer miss rates remain stubbornly high, hovering above 8% for esophageal and gastric cancers, with some longitudinal estimates reaching as high as 11.3% over a three-year window.
The AI Revolution: From "Spotter" to "GPS"
The success of Artificial Intelligence (AI) in lower GI endoscopy offers a roadmap for the future. A 2024 meta-analysis of 28 randomized controlled trials, involving nearly 24,000 patients, demonstrated that AI-assisted colonoscopy yields a 20% increase in adenoma detection rates and a 55% decrease in adenoma miss rates.
However, the application of AI in the upper GI tract requires a paradigm shift. In the lower GI, AI functions primarily as a "spotter," flagging suspicious polyps. In the upper GI, AI must function more like a sophisticated GPS.
The current generation of upper GI AI technology focuses on landmark verification. Before the scope is withdrawn, the AI tracks whether the endoscopist has successfully navigated through every required anatomical checkpoint and viewed each area with sufficient image quality. By confirming in real-time that no "blind spots" remain, the technology forces a level of scrutiny that human oversight—subject to fatigue and cognitive displacement—sometimes misses.
Operational Implications and Financial Barriers
The current US reimbursement structure presents a significant hurdle to this necessary evolution. Endoscopy billing is largely binary: a base payment for the procedure, with a flat increment if a biopsy or resection is performed. This structure fails to account for the time and precision required for a high-quality upper GI exam. There is currently no financial signal to incentivize a physician to spend an extra three minutes ensuring a perfect view of the duodenum or the gastric fundus.
Furthermore, training paradigms in the United States emphasize colonoscopy proficiency over EGD nuance. As the specialist shortage worsens, the pressure to maintain throughput becomes even more acute. Without a standardized quality framework for EGD, clinicians are incentivized to perform these exams as quickly as possible to move on to the next patient.
The Roadmap for Improvement
If the industry is to rectify this imbalance, the development of upper GI quality standards must follow a deliberate, three-stage sequence:
- Defining Quality Indicators: The gastroenterology community has begun publishing guidelines for upper GI quality indicators. These must be universally adopted and integrated into clinical workflows.
- Technological Integration: The roadmap for AI must prioritize landmark verification first, establishing a baseline of "complete coverage" before moving toward the detection of dysplasia in Barrett’s esophagus or gastric intestinal metaplasia—the upper GI counterparts to colon adenomas.
- Efficiency Through Automation: AI can solve the documentation bottleneck. By automatically injecting findings into procedure reports, AI reduces the manual labor burden on clinicians. In a combined session, where documentation requirements are doubled, these time savings are substantial, providing a clear Return on Investment (ROI) for health systems.
Implications for the Future of Gastroenterology
The transition toward AI-supported, quality-focused upper GI endoscopy is no longer a speculative future; it is an operational necessity. As we move toward 2037, the health systems that survive will be those that view "quality" and "efficiency" as two sides of the same coin.
The lower GI experience proved that the clinical community will embrace technological support when the evidence for improved outcomes is undeniable. The "institutional reluctance" that once hindered the adoption of colon-based AI has largely evaporated, and this creates a unique opening for the upper GI sector.
We must stop treating the EGD as an afterthought. By applying the same rigor to the stomach and esophagus that we apply to the colon, we can reduce the unacceptably high miss rates for upper GI cancers and ensure that the convenience of a combined procedure does not come at the cost of patient safety. The tools exist. The clinical precedent is set. The only remaining task is to commit the same level of discipline and institutional support to the upper GI tract that the colon has enjoyed for decades.
In the final analysis, the stomach and esophagus deserve the same standard of care as the colon. It is time for the infrastructure of our specialty to reflect that fundamental medical truth.
